Theravance Biopharma (NASDAQ:TBPH) Rating Reiterated by HC Wainwright

HC Wainwright reiterated their buy rating on shares of Theravance Biopharma (NASDAQ:TBPH) in a research note released on Monday morning, Benzinga reports. The firm currently has a $15.00 price target on the biopharmaceutical company’s stock.

Several other analysts have also issued reports on the stock. StockNews.com lowered shares of Theravance Biopharma from a buy rating to a hold rating in a research report on Saturday, August 10th. TD Cowen lowered their price target on Theravance Biopharma from $10.00 to $9.00 and set a hold rating on the stock in a research note on Tuesday, August 6th. Leerink Partnrs lowered Theravance Biopharma from a strong-buy rating to a hold rating in a research note on Tuesday, August 6th. Finally, Leerink Partners cut shares of Theravance Biopharma from an outperform rating to a market perform rating and cut their price target for the stock from $15.00 to $10.00 in a research note on Tuesday, August 6th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, Theravance Biopharma currently has a consensus rating of Hold and a consensus target price of $13.75.

Theravance Biopharma Stock Performance

Theravance Biopharma stock opened at $8.21 on Monday. The business’s 50-day simple moving average is $8.73 and its 200-day simple moving average is $8.86. Theravance Biopharma has a 52 week low of $7.44 and a 52 week high of $11.71. The firm has a market capitalization of $401.63 million, a PE ratio of -9.55 and a beta of 0.24.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.25). Theravance Biopharma had a negative return on equity of 21.29% and a negative net margin of 73.61%. The business had revenue of $14.26 million for the quarter, compared to analyst estimates of $15.81 million. During the same quarter last year, the firm earned ($0.28) earnings per share. Research analysts forecast that Theravance Biopharma will post -1.04 earnings per share for the current year.

Insider Buying and Selling at Theravance Biopharma

In related news, major shareholder Eli Samaha purchased 999,800 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The shares were acquired at an average cost of $7.80 per share, with a total value of $7,798,440.00. Following the completion of the purchase, the insider now directly owns 9,511,150 shares of the company’s stock, valued at $74,186,970. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the sale, the senior vice president now owns 335,965 shares of the company’s stock, valued at approximately $3,023,685. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Eli Samaha bought 999,800 shares of the company’s stock in a transaction on Wednesday, August 7th. The shares were acquired at an average price of $7.80 per share, with a total value of $7,798,440.00. Following the transaction, the insider now directly owns 9,511,150 shares in the company, valued at approximately $74,186,970. The disclosure for this purchase can be found here. Corporate insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On Theravance Biopharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TBPH. China Universal Asset Management Co. Ltd. boosted its holdings in Theravance Biopharma by 66.4% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,583 shares of the biopharmaceutical company’s stock worth $86,000 after buying an additional 3,824 shares during the last quarter. Gerber LLC bought a new stake in Theravance Biopharma in the fourth quarter valued at approximately $112,000. Hsbc Holdings PLC acquired a new stake in Theravance Biopharma in the second quarter worth $108,000. XTX Topco Ltd bought a new position in shares of Theravance Biopharma during the second quarter worth $129,000. Finally, State Board of Administration of Florida Retirement System grew its holdings in shares of Theravance Biopharma by 28.2% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 22,671 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 4,990 shares during the period. Institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.